Efficacy and safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Paller, Amy S.
Siegfried, Elaine C.
Simpson, Eric L.
Wollenberg, Andreas
Gonzalez, Mercedes E.
Sidbury, Robert
Lockshin, Benjamin
Xiao, Jing
O'Malley, John T.
Bansal, Ashish
机构：
来源：
ALLERGY AND ASTHMA PROCEEDINGS | 2022年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：561 / 561
页数：1
相关论文
共 50 条
  • [31] Dupilumab treatment improves health-related quality of life in children aged 6 months-5 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Zhang, Haixin
    Wang, Zhixiao
    Rodriguez Marco, Ainara
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E104 - E105
  • [32] P6.09 Hematologic laboratory parameters in adults and children aged 6 months to 18 years with moderate-to-severe atopic dermatitis treated with -dupilumab
    Paller, A. S.
    Siegfried, E. C.
    Zhang, H.
    Khokhar, F. A.
    Homann, A.
    Gonzalez, T.
    ALLERGOLOGIE, 2022, 45 (08) : 624 - 624
  • [33] DUPILUMAB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND THEIR CAREGIVERS
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Zhang, Haixin
    Wang, Zhixiao
    Marco, Ainara Rodriguez
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 49 - 49
  • [34] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [35] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [36] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [37] Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Siegfried, Elaine C.
    Cork, Michael J.
    Arkwright, Peter D.
    Wollenberg, Andreas
    Eichenfield, Lawrence F.
    Ramien, Michele
    Khokhar, Faisal A.
    Chen, Zhen
    Zhang, Annie
    Cyr, Sonya L.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [38] Dupilumab treatment normalizes skin barrier function in children aged 6-11 years with moderate-to-severe atopic dermatitis
    Cork, Michael J.
    Leung, Donald
    Ong, Peck
    Danby, Simon
    Ramirez-Gama, Marco
    Garcia, Shannon
    Patricia, Taylor
    Byers, Rob
    Matcher, Stephen
    Zahn, Joseph
    Bologna, Gabriel
    Zhang, Annie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I30 - I30
  • [39] Laboratory Safety From a 16-week Phase 3 Study of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 88 - 89
  • [40] Laboratory safety from a 16-week phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345